PARIS and NEW YORK, April 14, 2015 /PRNewswire/ -- Cenexi, with operations in Europe and global regulatory approvals from ANSM (EU), ANVISA (Brazil), PMDA (Japan), USFDA (USA) and KFDA (Korea), specializes in drug formulation for solid dosage and liquid steriles manufacturing. Top executives and technology experts at Cenexi plan to leverage the opportunity provided by INTERPHEX to share their extensive knowledge of development and manufacturing for the bio/pharmaceutical industries with industry leaders and subject matter experts from more than 48 countries.
Scientific leaders and purchasers of services such as those offered by Cenexi are seeking to find new, more cost-effective alternatives to existing processes through evaluation of the full range of globally competitive solutions. Philippe Mougin, CEO and founder of Cenexi Group, said: "Cenexi's operations are inspected by regulatory agencies from around the world, and want our potential partners in North America to be aware of our capabilities and quality record. We believe that INTERPHEX, which is located in New York City, provides the ideal setting to achieve this goal."
INTERPHEX, the International Pharmaceutical Expo, is sponsored by the Parenteral Drug Association (PDA), and is a gathering place for bio/pharmaceutical development and manufacturing solution providers like Cenexi. It brings together more than 600 suppliers and over 12,000 global pharmaceutical and biotechnology industry professionals through a unique combination of exhibition, education, workshop and partnering opportunities and networking events. INTERPHEX will take place April 21-23, 2015 at the Javits Center in New York City.
Cenexi Group includes Cenexi Paris, Fontenay-sous-Bois, and Osny, France, and Cenexi-Laboratories Thissen in Braine L'Alleud, Belgium. Cenexi Services; entity managing Development Centers on each site, is approved by the French Ministry of Research and Technology for the Research Tax Credit (CIR) and is a holder of ISO 14001 certification. Visit www.cenexi.com
For further information:
SOURCE Cenexi Group